Coluracetam

    Researchedby:
    Last Updated: September 28, 2022

    Coluracetam (MKC-231) is a racetam drug purported to be a cognitive enhancing drug. It is able to preserve choline uptake into neurons when they are otherwise impaired, but currently there is no evidence for inherent nootropic effects.

    Coluracetam is most often used for

    Summary

    Coluracetam (MKC-231) is a synthetic racetam drug purported to be a nootropic compound. It does not have a large body of evidence investigating it, but the mechanisms of action (as well as structure) appear to be very distinct from other racetam compounds like Piracetam or Aniracetam.

    Coluracetam appears to interact with a process known as high affinity choline uptake (HACU for short), which is the rate-limiting step of drawing choline into a neuron for synthesis into the neurotransmitter acetylcholine. Increasing the HACU rate appears to increase the activity of cholinergic neurons, so it is a desired target for cognitive enhancement.

    Interventions in rats (as there is no human evidence currently) support the usage of coluracetam at very low oral doses to preserve HACU that is otherwise impaired by the use of research drugs that are known to impair HACU. The limited evidence looking at the inherent effects of coluracetam on the HACU of normal neurons has failed to find any significant interaction.

    Coluracetam has also been noted to associate with choline transporters physically, but it is not known exactly what it does once associated.

    Overall, there is currently insufficient evidence to support the usage of coluracetam for cognitive enhancement. Further studies are needed to see if it has a therapeutic role in instances where HACU may be impaired (such as Alzheimer's disease).

    What are other names for Coluracetam

    Note that Coluracetam is also known as:
    • MKC-231
    • BCI-540
    • 2-(2-oxypyrrolidin-1-yl)-N-(2 3-dimethyl-5 6 7 8-tetrahydrofuro(2 3-b)quinolin-4-yl)acetoamide

    Dosage information

    The animal research on coluracetam uses an oral dose of 300-3,000mcg/kg bodyweight, which is roughly translated into a human dose of 48-480mcg/kg or (for a 150lb person) 3.2-32.7mg overall.

    It appears to have very rapid kinetics, with a peak in blood at around 30 minutes and on the decline within 3 hours. Due to this, supplementation may be time-dependent in relation to activity.